Q32 Bio Inc.(QTTB)是一家開創性的生物科技公司,專注於開發先進的抗體療法,用於自身免疫性疾病及免疫反應優化。憑藉其專有技術平台,公司正在建立強大的治療候選藥物管線,旨在恢復免疫平衡並解決重大未被滿足的醫療需求。在經驗豐富的管理團隊指導下,並透過策略合作得到加強,Q32 Bio處於有利地位,能夠透過專注的研發計劃為醫療保健作出有影響力的貢獻,並為其股東創造可觀的長期價值。
財務指標
營業收入
2026-06-30
$0
2026-03-31
$0
2025-12-31
$53.73M
2025-09-30
$0
營業支出
2026-06-30
$9.03M
2026-03-31
$7.72M
2025-12-31
$7.85M
2025-09-30
$7.57M
淨利潤
2026-06-30
-$8.94M
2026-03-31
-$7.6M
2025-12-31
$57.73M
2025-09-30
-$7.38M
淨利潤率
2026-06-30
--
2026-03-31
--
2025-12-31
107.43%
2025-09-30
--
每股收益
2026-06-30
$-0.44
2026-03-31
$-0.54
2025-12-31
$4.58
2025-09-30
$-0.60
息稅折舊攤銷前利潤
2026-06-30
-$8.86M
2026-03-31
-$7.63M
2025-12-31
$58.02M
2025-09-30
-$6.99M
有效稅率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
項目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
營業收入
$0
$0
$53.73M
$0
營業支出
$9.03M
$7.72M
$7.85M
$7.57M
淨利潤
-$8.94M
-$7.6M
$57.73M
-$7.38M
淨利潤率
--
--
107.43%
--
每股收益
$-0.44
$-0.54
$4.58
$-0.60
息稅折舊攤銷前利潤
-$8.86M
-$7.63M
$58.02M
-$6.99M
有效稅率
--
--
--
--
常見問題
QTTB is the ticker symbol for Q BioMed Inc., a biotechnology company focused on developing and commercializing therapeutics and diagnostic products for underserved medical conditions. The stock represents an ownership stake in the company and trades on U.S. over-the-counter markets. Investors can review the latest QTTB company profile and market data on the stock detail page for current information.
Several factors can influence QTTB's share price, including clinical trial results, regulatory decisions from agencies such as the FDA, product development milestones, financing activities, and changes in the company's financial condition. Broader market sentiment toward small-cap biotechnology stocks and general economic conditions can also play a role. Because QTTB trades over the counter, liquidity and trading volume may amplify price movements relative to larger exchange-listed companies.
QTTB has historically shown significant price volatility, which is common among small-cap biotechnology companies with limited revenue and ongoing development programs. News about trials, regulatory filings, or financing can cause sharp moves. Trading on over-the-counter markets may further amplify swings due to thinner liquidity and wider bid-ask spreads. For current volatility measures such as beta or recent price ranges, refer to the latest data displayed on the QTTB stock page.
QTTB has not historically paid dividends, which is typical for development-stage biotechnology companies that reinvest available capital into research, clinical programs, and operations rather than returning cash to shareholders. Any future decision to initiate a dividend would depend on the company's financial position and strategic priorities. For the most current dividend status, check the dividend section of the QTTB stock detail page.
Key risks for QTTB include the possibility that product candidates fail in clinical development or do not receive regulatory approval, the need for additional capital that could dilute existing shareholders, and limited revenue relative to operating expenses. As an over-the-counter stock, QTTB may also face lower liquidity and less stringent reporting requirements than exchange-listed companies. These factors can contribute to substantial price swings.
Earnings information for QTTB, including quarterly and annual reports, can typically be found through the company's investor relations page, SEC filings such as 10-K and 10-Q reports, and financial data providers. These sources detail revenue, net income or loss, and operating expenses. The QTTB stock detail page may also summarize recent financial results and link to relevant filings for further review.